鲁抗医药：头孢呋辛酯干混悬剂通过一致性评价

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Cefuroxime Axetil dry suspension, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Drug Approval - The approval notification for Cefuroxime Axetil dry suspension is identified by certificate number 2025B02754 [1] - The drug is a prodrug of Cefuroxime and belongs to the second generation of cephalosporin antibiotics [1] Group 2: Mechanism and Efficacy - The mechanism of action involves inhibiting bacterial cell wall synthesis, preventing bacterial reproduction [1] - The drug exhibits broad-spectrum antibacterial activity against various pathogens, including Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, and others [1] - It also shows good efficacy against Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus species [1]